Living systematic review: 1. Introduction—the why, what, when, and how

…, G Rada, M Bagg, A Jones, P Ravaud… - Journal of clinical …, 2017 - Elsevier
Systematic reviews are difficult to keep up to date, but failure to do so leads to a decay in
review currency, accuracy, and utility. We are developing a novel approach to systematic …

Increasing value and reducing waste in biomedical research: who's listening?

…, PMM Bossuyt, DA Korevaar, ID Graham, P Ravaud… - The Lancet, 2016 - thelancet.com
The biomedical research complex has been estimated to consume almost a quarter of a trillion
US dollars every year. Unfortunately, evidence suggests that a high proportion of this sum …

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review

…, G Grasselli, D Tovey, P Ravaud… - Cochrane database …, 2023 - cochranelibrary.com
… We checked whether the results were unavailable because of the result’s P value, magnitude,
or direction. We considered the risk of bias due to missing results if one specified outcome …

A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease

…, F Vermeer, E Boersma, P Ravaud… - European heart …, 2003 - academic.oup.com
Aims To identify the characteristics, treatment, and outcomes of contemporary patients with
valvular heart disease (VHD) in Europe, and to examine adherence to guidelines. Methods …

[HTML][HTML] Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

…, M Resche-Rigon, R Porcher, P Ravaud… - JAMA internal …, 2021 - jamanetwork.com
Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …

Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?

…, C Gohlke-Bärwolf, E Boersma, P Ravaud… - European heart …, 2005 - academic.oup.com
… using a backward procedure with a threshold of P=0.05, except for the … P<0.25 were entered
into a multivariable Cox model and selected by a backward procedure with a threshold of P=…

[HTML][HTML] Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

…, T Papo, B Bonnotte, A Mahr, P Ravaud… - … England Journal of …, 2014 - Mass Medical Soc
… Twenty-five patients in each group (P=0.92) had severe adverse events; there were 44 events
in the azathioprine group and 45 in the rituximab group. Eight patients in the azathioprine …

Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration

…, D Moher, DG Altman, KF Schulz, P Ravaud… - Annals of internal …, 2008 - acpjournals.org
Adequate reporting of randomized, controlled trials (RCTs) is necessary to allow accurate
critical appraisal of the validity and applicability of the results. The CONSORT (Consolidated …

What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?

…, EG Butchart, P Ravaud… - European heart …, 2007 - academic.oup.com
… Variables with P < 0.25 were entered in a multivariable logistic model and were selected
using a backward procedure with a threshold of P = 0.05. An internal validation of the model …

Infective endocarditis in Europe: lessons from the Euro heart survey

…, C Gohlke-Bärwolf, EG Butchart, P Ravaud… - Heart, 2005 - heart.bmj.com
P Ravaud2, … % in Eastern, and 2.9% in Mediterranean Europe (p = 0.34). IE occurred on
native valves in … was 10.4% and 15.6% among the patients who underwent surgery (p = 0.42). …